Huntington's Pill Shows Breakthrough Results in NZ Trial

Families living with Huntington's disease in New Zealand are celebrating what experts are calling "unbelievable" results from a trial that could change everything for this devastating condition.

US biotech company Skyhawk Therapeutics started testing its drug SKY-0515 on patients in New Zealand and Australia a year ago. The treatment works like a stop sign in RNA, preventing the body from producing the toxic protein that destroys brain cells and causes symptoms to worsen.

The results have stunned even the medical experts involved. Patients taking the daily pill showed no disease progression at all, compared to the typical physical decline seen in untreated patients.

"I don't think we were expecting anything quite as good as this," said Dr. Greg Finucan, a neuropsychiatrist and chief medical adviser for the Huntington's Association. His excitement is grounded in solid science: blood tests showed a significant drop in the mutant protein responsible for the disease.

Huntington's disease affects about one in 10,000 people worldwide. Each child of an affected parent has a 50 percent chance of inheriting the faulty gene, with symptoms typically emerging between ages 35 and 45. The rare brain disorder progressively breaks down nerve cells, and until now, there has been no cure or effective treatment to slow its progression.

Why This Inspires

What makes this breakthrough particularly meaningful is its accessibility. Last year, researchers showed that gene therapy requiring injections directly into the brain could slow progression to about 25 percent of normal rates. That treatment was expensive enough to "build a new hospital," according to Finucan.

This new pill offers similar or better results that patients can take at home. No hospital visits, no invasive procedures, just a daily medication that appears to halt the disease entirely.

Jo Dysart, chief executive of the Huntington's Disease Association Auckland, was nearly speechless reading the results. "For our Huntington's population in New Zealand, it's amazing, groundbreaking. This is real hope," she said.

Her organization supports 1,500 people affected by the disease in Auckland and the North Shore alone, including those living with symptoms, at-risk family members, and people who test positive for the gene. These families have learned to be cautious about hope, she explained, but this breakthrough feels different.

The treatment is now moving into phase two trials, testing 520 people at over 52 sites around the world. Researchers need to confirm there are no serious side effects and that the positive results hold up with larger numbers of patients.

For families who have watched this disease pass through generations with no way to stop it, a simple pill that could halt progression entirely represents more than medical progress—it represents restored futures.